tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2015-1-24-30tumors-35Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL REPORTSНОВЫЕ ВОЗМОЖНОСТИ РЕГУЛЯЦИИ ПРОТИВООПУХОЛЕВОГО ИММУННОГО ОТВЕТАNew capabilities of regulation of antitumor immune responseКАДАГИДЗЕЗ. Г.KadagidzeZ. G.kad-zaira@yandex.ruЧЕРТКОВАА. И.ChertkovaA. I.ЗАБОТИНАТ. Н.ZabotinaT. N.КОРОТКОВАО. В.KorotkovaO. V.СЛАВИНАЕ. Г.SlavinaE. G.БОРУНОВАА. А.BorunovaA. A.НИИ клинической онкологии ФГБУ «РОНЦ им. Н. Н. Блохина»Russian Federation201520052015012634Copyright © КАДАГИДЗЕ З.Г., ЧЕРТКОВА А.И., ЗАБОТИНА Т.Н., КОРОТКОВА О.В., СЛАВИНА Е.Г., БОРУНОВА А.А., 20152015КАДАГИДЗЕ З.Г., ЧЕРТКОВА А.И., ЗАБОТИНА Т.Н., КОРОТКОВА О.В., СЛАВИНА Е.Г., БОРУНОВА А.А.Kadagidze Z.G., Chertkova A.I., Zabotina T.N., Korotkova O.V., Slavina E.G., Borunova A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/35

Опухоль обладает различными механизмами, способными разрушать иммунологическую защиту. Популяции регуляторных клеток наряду с другими факторами обеспечивают «ускользание» опухоли от иммунологического надзора. В нашей лаборатории было проведено изучение особенностей количественных изменений некоторых субпопуляций лимфоцитов периферической крови у первично-операбельных больных раком молочной железы (РМЖ) и диссеминированной меланомой на разных этапах опухолевого роста и в процессе противоопухолевой терапии. У 94,5% больных РМЖ было обнаружено повышение по сравнению с контролем количества NKT-клеток с фенотипом CD45+CD3+CD16+CD56+, у 78% повышение количества CD8+CD28- Т-клеток, и у 20,5% больных повышение количества регуляторных CD4+CD25+FOXP3+ Т-клеток. Выявлена зависимость изменений количества этих клеток от стадии заболевания: у пациенток с I и II стадиями заболевания отмечалось статистически значимое повышение процента CD8+CD28- Т-клеток и CD45+CD3+CD16+CD56+ NKT-клеток по сравнению с донорами. В то же время у пациенток с III стадией количество клеток обеих популяций снижалось и практически не отличалось от нормы. Подобная динамика количественных изменений была характерна и для основных популяций клеток-эффекторов противоопухолевого иммунитета. При обследовании больных диссеминированной меланомой было обнаружено, что отсутствие повышения количества цитотоксических CD45+CD8+CD11b+ Т-клеток в процессе лечения дендритноклеточной вакциной (ДКВ), по-видимому, является показанием к прекращению вакцинотерапии, а исходно повышенное количество CD3+CD8+CD16+ NKT-клеток может служить основанием для отказа от ДКВ. Приводится краткое описание основных ко-ингибиторных рецепторов Т-клеток и моноклональных антител, блокирующих ингибиторные молекулы на иммунокомпетентных и опухолевых клетках, с целью повышения эффективности противоопухолевого иммунного ответа. Обнадеживающие клинические результаты были получены при применении анти-CTLA-4 (ипилимумаб) и анти-PD-1 (ниволумаб) моноклональных антител.

The tumor has different mechanisms capable of destroying the immunological protection. Population of regulatory cells, along with other factors provide “escape” of the tumor from immune surveillance. In our laboratory, we studied the features of quantitative changes of some subpopulations of peripheral blood lymphocytes in primary operable breast cancer (BC) and melanoma at different stages of tumor growth and in the process of tumor therapy. In 94.5% of patients with breast cancer were found to increase compared to the control amount of NKT-cells with the phenotype CD45+CD3+ CD16+CD56+, 78% increase in number of CD8+CD28– T-cells, and 20.5% increase in the number of patients Regulatory CD4+CD25+FOXP3+ T cells. Was found to depend on changes in the number of these cells from the stage of the disease. Patients with stage I and II disease there was a statistically significant increase in the percentage of CD8+CD28– T–cells and CD45+CD3+ CD16+CD56+ NKT-cells compared to the donor. At the same time in patients with stage III the number of cells of both populations declined and did not differ from the norm. Such dynamics of quantitative changes were typical for the main populations of effector cells antitumor immunity. In the evaluation of patients with disseminated melanoma was found that no increase in the number of cytotoxic CD45+CD8+CD11b+ T cells in the treatment dendritic cell vaccine (DCV) appears to be an indication to stop vaccine therapy, initially increased amount of CD3+CD8+CD16+. NKT-cells may serve as grounds for refusal of DCV. A brief description of the major co-receptor inhibitor of T-cells, and monoclonal antibodies that block the inhibitory molecule on immune and tumor cells in order to increase the efficiency of anti-tumor immune response. Encouraging clinical results have been obtained by using anti-CTLA-4 (ipilimumab), and anti-PD-1 (nivolumab) monoclonal antibodies.

регуляторные Т-клеткиNKT-клеткимеланомарак молочной железыко-ингибиторные и ко-стимуляторные рецепторы Т-клетоктаргетная терапияregulatory T-cellsNKT-cellsmelanomabreast cancerco-inhibitory and co-stimulatory receptors of T celltargeted therapyReferencesКадагидзе З. Г., Черткова А. И., Славина Е. Г. NKT клетки и противоопухолевый иммунитет. // РБЖ — 2011. — Том. 10, № 3 — Стр. 9. —15.Kadagidze Z.G., Chertkova A.I., Slavina E.G. NKT-cells and antitumor immunity. RBZh. 2011. vol.11, no.3, p.9–15.Кадагидзе З. Г., Черткова А. И., Славина Е. Г. Регуляторные Т-клетки и их роль в противоопухолевом иммунном ответе // Вопр. Онкол. — 2009. — Т. 55 — С. 269–277.Kadagidze Z.G., Chertkova A.I., Slavina E.G. Regulatory T-cells and its role in antitumor immune response. Voprosy Onkologii [Questions in Oncology]. 2009. vol.55, p.269–277.Berzofsky J. A., Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. // J. Immunol. — 2008. — Vol. 180. — P. 3627–3635.Berzofsky J. A., Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. // J. Immunol.— 2008.— Vol. 180.— P. 3627–3635.Berzofsky J. A., Terabe M. The contrasting roles of NKT cells in tumor immunity // Curr. Mol. Med. — 2009. — Vol. 9. — P. 667–672.Berzofsky J. A., Terabe M. The contrasting roles of NKT cells in tumor immunity // Curr. Mol. Med.— 2009.— Vol. 9.— P. 667–672.Bulliard Y., Jolicoeur R,. Windman M. et al. Activating Fc receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies // J. Exp. Med. — 2013. — Vol.210. — P.1685–1693.Bulliard Y., Jolicoeur R,. Windman M. et al. Activating Fc receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies // J. Exp. Med.— 2013.— Vol.210.— P.1685–1693.deLeeuw R.J., Kost S.E, Kakal J. A. et al. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. // Clin. Cancer Res. — 2012. — Vol. 18. — P. 3022–3029.deLeeuw R.J., Kost S.E, Kakal J. A. et al. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. // Clin. Cancer Res.— 2012.— Vol. 18.— P. 3022–3029.Dieu-Nosjean M–C., Antoine M., Danel C. Et al. Long-term survival for patients with non–small-cell lung cancer with intratumoral lymphoid structures // J. Clin. Oncol. — 2008. — Vol. 26. — P. 4410–4417. 4410–4417.Dieu-Nosjean M–C., Antoine M., Danel C. Et al. Long-term survival for patients with non–small-cell lung cancer with intratumoral lymphoid structures // J. Clin. Oncol.— 2008.— Vol. 26.— P. 4410–4417. 4410–4417.Eiro’N., Pidal I., Fernandez-Garcia B. et al. Impact of CD68/ (CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer // PLOS one. — 2012. — Vol.7. — Issue 12 — P. e52796. pone 0052796.Eiro’N., Pidal I., Fernandez-Garcia B. et al. Impact of CD68/ (CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer // PLOS one.— 2012.— Vol.7.— Issue 12 — P. e52796. pone 0052796.Facciabene A., Motz G. T., Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis // Cancer Res. — 2012 Vol. — 72. — P. 2162–2171.Facciabene A., Motz G. T., Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis // Cancer Res.— 2012 Vol.— 72.— P. 2162–2171.Filaci G., Fenoglio D., Fravega M. CD8+CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers // J. Immunol. — 2007. — Vol. 179. — P. 4323–4334.Filaci G., Fenoglio D., Fravega M. CD8+CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers // J. Immunol.— 2007.— Vol. 179.— P. 4323–4334.Filaci G., Rizzi M., Setti M. et al. Non-antigen-specific CD8+ T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation // Ann. NY Acad. Sci. — 2005. — Vol. 1050. P. 115–123.Filaci G., Rizzi M., Setti M. et al. Non-antigen-specific CD8+ T suppressorFinn O. J. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer // Ann Oncol. — 2012. — Suppl. 8viii 6–9.lymphocytes in diseases characterized by chronic immune responses and inflammation // Ann. NY Acad. Sci.— 2005.— Vol. 1050. P. 115–123.Hald S. M., Bremnes R. M., Al-Shibli K. et al. CD4/ CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy // Lung Cancer. — 2013. — Vol. 80. — P. 209–215. 209–215.Finn O. J. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer // Ann Oncol.— 2012.— Suppl. 8viii 6–9.Hino R, Kabashima K,, Kato Y. et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma // Cancer. — 2010. — Vol. 116 — P. 1757–1766.Hald S. M., Bremnes R. M., Al-Shibli K. et al. CD4/ CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy // Lung Cancer.— 2013.— Vol. 80.— P. 209–215. 209–215.Hodi F. S., Butler M., Oble D. A. et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients // Proc. Natl. Acad. Sci. U S A. — 2008. — Vol.105. — P.3005–3010.Hino R, Kabashima K,, Kato Y. et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma // Cancer.— 2010.— Vol. 116 — P. 1757–1766.Hodi F. S., O’Day S.J., McDermott D.F. et al. Improved survival with ipilimumab in patients with metastatic melanoma // N. Engl. J. Med. — 2010. — Vol. 363 — P.711–723.Hodi F.S., Butler M., Oble D.A. et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients // Proc. Natl. Acad. Sci. U S A.— 2008.— Vol.105.— P.3005–3010.Izhak L., Ambrosino E., Kato S. et al. Delicate balance among three types of T cells in concurrent regulation of tumor immunity // Cancer Res. — 2013. — Vol. 73. P. 1514–1523.Hodi F. S., O’Day S.J., McDermott D.F. et al. Improved survival with ipilimumab in patients with metastatic melanoma // N. Engl. J. Med.— 2010.— Vol. 363 — P.711–723.Karag z B., Bilgi O., G m s M. et al.CD8+CD28– cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients // Med. Oncol. — 2010. — Vol. 27. — P. 29–33.Izhak L., Ambrosino E., Kato S. et al. Delicate balance among three types of T cells in concurrent regulation of tumor immunity // Cancer Res.— 2013.— Vol. 73. P. 1514–1523.Keir M. E., Butte M. J., Freeman G. J., Sharpe A. H. PD-1 and its ligands in tolerance and immunity // Annu. Rev. Immunol. — 2008. — Vol. 26. — P.677–704.Karag z B., Bilgi O., G m s M. et al.CD8+CD28– cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients // Med. Oncol.— 2010.— Vol. 27.— P. 29–33.Kim P. S., Ahmed R. Features of responding T cells in cancer and chronic infection // Curr. Opin. Immunol. — 2010. — Vol. 22 — P. 223–230.Keir M. E., Butte M. J., Freeman G. J., Sharpe A. H. PD-1 and its ligands in tolerance and immunity // Annu. Rev. Immunol.— 2008.— Vol. 26.— P.677–704.Kyi C., Postow M. A. Checkpoint blocking antibodies in cancer immunotherapy // FEBS Lett. — 2014. — Vol. 588. — P. 368–376.Kim P. S., Ahmed R. Features of responding T cells in cancer and chronic infection // Curr. Opin. Immunol.— 2010.— Vol. 22 — P. 223–230.Li S-Y., Liu Y. Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137 // Clinical Pharmacol: Adv. Appl. — 2013. — Vol.5 (Suppl 1) — P. 47–53.Kyi C., Postow M. A. Checkpoint blocking antibodies in cancer immunotherapy // FEBS Lett.— 2014.— Vol. 588.— P. 368–376.Liakou C. I., Kamat A., Tang D. N. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients // Proc. Natl. Acad. Sci.U S A. — 2008. — Vol.105. — P.14987–14992.Li S-Y., Liu Y. Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137 // Clinical Pharmacol: Adv. Appl.— 2013.— Vol.5 (Suppl 1) — P. 47–53.Lippitz B. E. Cytokine patterns in patients with cancer: a systematic review // Lancet Oncol. — 2013. — Vol.14. — P. e218-e228.Liakou C. I., Kamat A., Tang D. N. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients // Proc. Natl. Acad. Sci.U S A.— 2008.— Vol.105.— P.14987–14992.Meloni F., Morosini M., Solari N. et al. Foxp3 expressing CD4+CD25+ and CD8+CD28– T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma // Hum Immunol. — 2006. — Vol. 67. — P. 1–12.Lippitz B. E. Cytokine patterns in patients with cancer: a systematic review // Lancet Oncol.— 2013.— Vol.14.— P. e218-e228.Monu N. R., Frey A. B. Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship // Immunol. Invest. — 2012. — Vol. 41. — P. 595–613.Meloni F., Morosini M., Solari N. et al. Foxp3 expressing CD4+CD25+ and CD8+CD28– T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma // Hum Immunol.— 2006.— Vol. 67.— P. 1–12.Najafian N., Chitnis T., Salama A.D, et al. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model // J Clin Invest. — 2003. — Vol. 112. — P.1037–1048.Monu N. R., Frey A. B. Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship // Immunol. Invest.— 2012.— Vol. 41.— P. 595–613.Postow M. A., Harding J., Wolchok J. D. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma // Cancer J. — 2012. — Vol. 18 — P. 153–159.Najafian N., Chitnis T., Salama A.D, et al. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model // J Clin Invest.— 2003.— Vol. 112.— P.1037–1048.Quezada S. A., Peggs K. S., Curran M. A., Allison J. P. CTLA4 blockade and GM–CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells // J. Clin. Invest. — 2006. — Vol.116. — P.1935–1945.Postow M. A., Harding J., Wolchok J. D. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma // Cancer J.— 2012.— Vol. 18 — P. 153–159.Senovilla L., Vacchelli E., Galon J. et al. Prognostic and predictive value of the immune infiltrate in cancer // OncoImmunol. — 2012. — Vol. 1 — P.1323–1343.Quezada S. A., Peggs K. S., Curran M. A., Allison J. P. CTLA4 blockade and GM–CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells // J. Clin. Invest.— 2006.— Vol.116.— P.1935–1945.Simpson T. R., Li F., Montalvo-Ortiz W. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma // J. Exp. Med. — 2013. — Vol. 210. — P. 1695–1710.Senovilla L., Vacchelli E., Galon J. et al. Prognostic and predictive value of the immune infiltrate in cancer // OncoImmunol.— 2012.— Vol. 1 — P.1323–1343.Subleski J. J., Jiang Q., Weiss J. M., Wiltrout R. H. The split personality of NKT cells in malignancy, autoimmune and allergic disorders // Immunotherapy. — 2011. — Vol. 10. — P. 1167–1184.Simpson T. R., Li F., Montalvo-Ortiz W. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma // J. Exp. Med.— 2013.— Vol. 210.— P. 1695–1710.Tarhini A. A., Edington H., Butterfield L. H. et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab // PLoS One. — 2014. — Vol. 9. — P. e87705.Subleski J. J., Jiang Q., Weiss J. M., Wiltrout R. H. The split personality of NKT cells in malignancy, autoimmune and allergic disorders // Immunotherapy.— 2011.— Vol. 10.— P. 1167–1184.Urbaniak-Kujda D., Kapelko-S owik K., Wo owiec D. et al. Increased percentage of CD8+CD28- suppressor lymphocytes in peripheral blood and skin infiltrates correlates with advanced disease in patients with cutaneous T-cell lymphomas // Postepy Hig Med Dosw. — 2009. — Vol. 63. — P. 355–359.Tarhini A. A., Edington H., Butterfield L. H. et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab // PLoS One.— 2014.— Vol. 9.— P. e87705.Vigan S., Perreau M., Pantaleo G., Harari A. Positive and negative regulation of cellular immune responses in physiologic conditions and diseases // Clin. Dev. Immunol. — 2012. — Vol. 2012–485781.Urbaniak-Kujda D., Kapelko-S owik K., Wo owiec D. et al. Increased percentage of CD8+CD28- suppressor lymphocytes in peripheral blood and skin infiltrates correlates with advanced disease in patients with cutaneous T-cell lymphomas // Postepy Hig Med Dosw.— 2009.— Vol. 63.— P. 355–359.Vonderheide R. H., Flaherty K. T., Khalil M. et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody // J Clin Oncol. — 2007. — Vol. 25 — P. 876–883.Vigan S., Perreau M., Pantaleo G., Harari A. Positive and negative regulation of cellular immune responses in physiologic conditions and diseases // Clin. Dev. Immunol.— 2012.— Vol. 2012–485781.Voron T., Marcheteau E., Pernot S.et al. Control of the immune response by pro-angiogenic factors // Front. Oncol. — 2014. — Vol. 4 — Article.70.Vonderheide R. H., Flaherty K. T., Khalil M. et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody // J Clin Oncol.— 2007.— Vol. 25 — P. 876–883.Wang S., Chen L. T lymphocyte co-signaling pathways of the B7-CD28 family // Cell Mol. Immunol. — 2004. — Vol. N 1. — P. 37–42.Voron T., Marcheteau E., Pernot S.et al. Control of the immune response by pro-angiogenic factors // Front. Oncol.— 2014.— Vol. 4 — Article.70.Watanabe N., Nakajima H. Coinhibitory molecules in autoimmune diseases. Clin. Dev. Immunol. — 2012. — Vol. 2012–269756.Wang S., Chen L. T lymphocyte co-signaling pathways of the B7-CD28 family // Cell Mol. Immunol.— 2004.— Vol. N 1.— P. 37–42.Weinberg A. D., Morris N. P., Kovacsovics-Bankowski M. et al. Science gone translational: the OX40 agonist story// Immunol Rev. — 2011. — Vol. 244 — P. 218–231.Watanabe N., Nakajima H. Coinhibitory molecules in autoimmune diseases. Clin. Dev. Immunol.— 2012.— Vol. 2012–269756.West E. E., Jin H-T., Rasheed A-U. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells // J. Clin. Invest. — 2013. — Vol. 123 — P. 2604–2615.Weinberg A. D., Morris N.P., Kovacsovics-Bankowski M. et al. Science gone translational: the OX40 agonist story// Immunol Rev.— 2011.— Vol. 244 — P. 218–231.Wherry E. J., Ha S. J., Kaech S. M. Molecular signature of CD8+ T cell exhaustion during chronic viral infection // Immunity. — 2007. — Vol. 27 — P. 670–684.West E. E., Jin H-T., Rasheed A-U. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells // J. Clin. Invest.— 2013.— Vol. 123 — P. 2604–2615.Whiteside T. L. What are regulatory T cells (Treg) regulating in cancer and why? // Semin. Cancer Biol. — 2012. — Vol. 22. — P. 327–334.Wherry E. J., Ha S. J., Kaech S. M. Molecular signature of CD8+ T cell exhaustion during chronic viral infection // Immunity.— 2007.— Vol. 27 — P. 670–684.Wolchok J. D., Kluger H., Callahan M. K. et al. Nivolumab plus ipilimumab in advanced melanoma // N. Engl. J. Med. — 2013. — Vol.369. — P.122–133.Whiteside T. L. What are regulatory T cells (Treg) regulating in cancer and why? // Semin. Cancer Biol.— 2012.— Vol. 22.— P. 327–334.Wolchok J. D., Kluger H., Callahan M. K. et al. Nivolumab plus ipilimumab in advanced melanoma // N. Engl. J. Med.— 2013.— Vol.369.— P.122–133Wolchok J. D., Kluger H., Callahan M. K. et al. Nivolumab plus ipilimumab in advanced melanoma // N. Engl. J. Med.— 2013.— Vol.369.— P.122–133

The authors declare that there are no conflicts of interest present.